Skip to content
Oncology Research Hub

Los Angeles, California

Cancer clinical trials in Los Angeles, CA

384 cancer studies are recruiting participants at sites in Los Angeles as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Los Angeles at a glance

  • 384 studies are recruiting at a site in Los Angeles.
  • By phase: Early Phase 1 (5), Phase 1 (63), Phase 1/2 (87), Phase 2 (80), Phase 2/3 (10), Phase 3 (86), Phase 4 (2), No phase (25), Observational (26). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (236), university, hospital or other (126), government (22).
  • By research area: Breast Cancer (115), Lung Cancer (97), Prostate Cancer (64), Lymphoma (60), Pancreatic Cancer (26), Melanoma (22).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Los Angeles

Basic details from each study's public record (the 30 most recently updated of 384). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

    • Phase 2
    • Ages 18 and older
    • Female participants
    Sponsor
    Stephen Shiao
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT05491226 · updated
  2. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study sites
    Ellison Medical Institute · University of California Los Angeles · Valkyrie Clinical Trials
    Registry record
    NCT06324357 · updated
  3. ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Stephen Shiao
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07015853 · updated
  4. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Ellison Medical Institute
    Registry record
    NCT05894239 · updated
  5. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    START Los Angeles
    Registry record
    NCT07488676 · updated
  6. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    USC / Norris Comprehensive Cancer Center
    Registry record
    NCT03418961 · updated
  7. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Keck Medicine of USC Koreatown · Los Angeles General Medical Center · USC / Norris Comprehensive Cancer Center
    Registry record
    NCT05372640 · updated
  8. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cedars-Sinai Medical Center · The Angeles Clinic and Research Institute - West Los Angeles Office
    Registry record
    NCT05564377 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Lung cancer studies recruiting in Los Angeles

  1. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    USC/Norris Comprehensive Cancer Center
    Registry record
    NCT07063745 · updated
  2. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    UCLA Hematology Oncology - Main Site
    Registry record
    NCT07111520 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study sites
    Cedars-Sinai Medical Center · START LA · Valkyrie Clinical Trials
    Registry record
    NCT07659782 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
    Registry record
    NCT04267848 · updated
  5. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT04665739 · updated
  6. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Valkyrie Clinical Trials
    Registry record
    NCT04886804 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Los Angeles

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    UCLA / Jonsson Comprehensive Cancer Center
    Registry record
    NCT04423211 · updated
  2. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Keck Medicine of USC Koreatown · Los Angeles General Medical Center · USC / Norris Comprehensive Cancer Center
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Melanoma studies recruiting in Los Angeles

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Los Angeles General Medical Center · USC / Norris Comprehensive Cancer Center
    Registry record
    NCT07068074 · updated
  2. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cedars-Sinai Medical Center · Los Angeles General Medical Center · The Angeles Clinic and Research Institute - West Los Angeles Office
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Lymphoma studies recruiting in Los Angeles

  1. A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

    • No phase
    • Ages 1 to 25
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Los Angeles
    Registry record
    NCT05621291 · updated
  2. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Valkyrie Clinical Trials
    Registry record
    NCT06806033 · updated
  3. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT07221500 · updated
  4. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Children's Hospital Los Angeles
    Registry record
    NCT06173518 · updated
  5. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cedars-Sinai Medical Center ( Site 0115)
    Registry record
    NCT06717347 · updated
  6. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cedar Sinai Cancer Center ( Site 0119)
    Registry record
    NCT07519772 · updated
  7. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente Los Angeles Medical Center · Kaiser Permanente West Los Angeles
    Registry record
    NCT04269902 · updated
  8. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cedars-Sinai Medical Center · Children's Hospital Los Angeles · Mattel Children's Hospital UCLA
    Registry record
    NCT04546399 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Los Angeles

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cedars-Sinai Medical Center ( Site 0110)
    Registry record
    NCT04924075 · updated
  2. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US027 · Investigative Site US036 · Investigative Site US048
    Registry record
    NCT07522073 · updated
  3. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study sites
    Cedars-Sinai Medical Center · START- Los Angeles · Valkyrie Clinical Trials
    Registry record
    NCT07644559 · updated
  4. Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

    • No phase
    • Ages 18 to 99
    • All sexes
    Sponsor
    Cedars-Sinai Medical Center
    Study site
    Cedars-Sinai Medical Center
    Registry record
    NCT04907643 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Los Angeles, CA on ClinicalTrials.gov.

Ask about studies near Los Angeles

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call